Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285196 | 0.90 | LMNA (0.48) | ALDH1A1HPGDPOLBLMNA | |
| SCHEMBL2765669 | 0.89 | TP53 (0.40) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3284611 | 0.88 | TP53 (0.47) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3285286 | 0.88 | TP53 (0.47) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3284505 | 0.87 | TP53 (0.44) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3286715 | 0.87 | TP53 (0.44) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3284178 | 0.87 | TP53 (0.48) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3284580 | 0.86 | TP53 (0.42) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL8261092 | 0.85 | TP53 (0.41) | ALDH1A1HPGDPOLBLMNAF10 | |
| SCHEMBL3286834 | 0.85 | TP53 (0.41) | ALDH1A1HPGDPOLBLMNAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1858890-B1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-04-14 | — | — | EP | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| WO-2006089909-A1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | L3MBTL1 4767/4885ALDH1A1 1594/4885HPGD 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.